SynthesisFrontiers in endocrinology2025
Hypertriglyceridemia is a dose-dependent risk factor for type 2 diabetes mellitus: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between triglyceride levels and upper urinary tract calcium stones recurrence.BMC nephrology · 2026Article
- Five-Year outcomes of a digitally delivered carbohydrate-reduced nutrition intervention for prediabetes: durability of diabetes prevention.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The prevalence of type 2 diabetes mellitus (T2DM) has more than doubled in the past 20 years. Most T2DM cases are preventable if risk factors are eliminated early. Hypertriglyceridemia (HTG) is also a potential but modifiable risk factor, and has a high prevalence as well. We aimed to investigate the dose-dependent effect of HTG on the development of T2DM. Methods: We carried out a systematic search in three databases (MEDLINE, Embase, and CENTRAL) on 9 November 2023. We investigated an adult population with different triglyceride levels (exposure). The outcome of interest was the development of T2DM. Pooled hazard ratio (HR), odds ratio (OR), and mean differences (MDs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Risk of bias was assessed with the Quality In Prognosis Studies (QUIPS) tool. The protocol was registered in PROSPERO (CRD42023471288). Results: We identified 31,098 articles and included 101 in our meta-analysis. We found that people with HTG had more than a 1.5-fold higher risk (HR: 1.73 [1.31; 2.29]) of developing T2DM. Those who had their TG levels between 1.7 and 2.3 mmol/L had a 42% higher risk (HR: 1.42 [1.13; 1.79]), while those with TG levels above 2.3 mmol/L had an even higher risk for T2DM (HR: 1.82 [1.18; 2.87]) compared with patients with TG levels below 1.7 mmol/L. When investigating the hypertriglyceridemic waist phenotype, we found that only those with increased waist circumference had a higher risk in both sex groups among the different phenotype groups (female: HR: 2.86 [1.59; 5.14], male: HR: 3.31 [1.57; 7.27]). Conclusion: HTG is a dose-dependent risk factor for T2DM. Elevated waist circumference may have an even more important role in the development of T2DM than HTG. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42023471288.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.